Analytical Data
-
Gene name
HLA-A*02:01&B10M&Survivin(TLPPAWQPFL) Monomer
- Application
-
Alternative Names
BIRC5; API4; EPR-1; Baculoviral Inhibitor Of Apoptosis Repeat Containing 5; Apoptosis Inhibitor 4; Survivin Variant 3 Alpha
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
O70201
-
Expression Region
Met1~Ala140
-
Molecular Weight
25kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*02:01, specifically its complex with the peptide survivin (TLPPAWQPFL), focuses on understanding the immune response to cancer. HLA-A*02:01 is one of the most prevalent class I human leukocyte antigens (HLAs) and plays a critical role in presenting intracellular peptides to CD8+ T cells, which are essential for cytotoxic immune responses. Survivin, an important regulator of apoptosis and a component of the chromosomal passenger complex, is often overexpressed in various tumors, making it an attractive target for cancer immunotherapy. The monomeric recombinant protein of HLA-A*02:01 bound to the survivin peptide facilitates detailed studies of T cell recognition and interaction, thereby aiding in the identification of effective therapeutic strategies. By examining this complex, researchers aim to elucidate the mechanisms of immune recognition and to develop peptide-based vaccines or adoptive T cell therapies that could potentially enhance anti-tumor immunity in HLA-A*02:01 positive patients. This research is crucial for advancing personalized cancer treatment and improving patient outcomes through innovative immunotherapeutic approaches.
